1.Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362(15):1417-1429.
2.Chaganti S, Illidge T, Barrington S, Mckay P, Linton K, Cwynarski K, et al. Guidelines
for the management of diffuse large B-cell lymphoma. Br J Haematol. 2016;174(1):43-56.
3.Factors A. A predictive model for aggressive non-Hodgkin's lymphoma. The International
Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987-994.
4.Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosbythompson A, et al. An
enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large
B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837-842.
5.D H, RA W. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
6.Salvagno GL, Sanchisgomar F, Picanza A, Lippi G. Red blood cell distribution width:
A simple parameter with multiple clinical applications. Crit Rev Clin Lab Sci. 2015;52(2):86-105.
7.Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, et al. Cytokine profile and
prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer.
Br J Cancer. 2015;112(6):1088 -1097.
8.Stotz M, Pichler M, Absenger G, Szkandera J, Arminger F, Schaberlmoser R, et al. The
preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with
stage III colon cancer. Br J Cancer. 2014;110(2):435-440.
9.Schleicher RI, Reichenbach F, Kraft P, Kumar A, Lescan M, Todt F, et al. Platelets
induce apoptosis via membrane-bound FasL. Blood. 2015;126(12):1483-1493.
10.Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision
of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390.
11.Li ZM, Huang JJ, Xia Y, Sun J, Huang Y, Wang Y, et al. Blood Lymphocyte-to-Monocyte
Ratio Identifies High-Risk Patients in Diffuse Large B-Cell Lymphoma Treated with
R-CHOP. Plos One. 2012;7(7):e41658.
12.Xiong SD, Pu LF, Wang HP, Hu LH, Ding YY, Li MM, et al. Neutrophil CD64 Index as a
superior biomarker for early diagnosis of infection in febrile patients in the hematology
department. Clin Chem Lab Med. 2017;55(1):82-90.
13.Troppan KT, Schlick K, Deutsch A, Melchardt T, Egle A, Stojakovic T, et al. C-reactive
protein level is a prognostic indicator for survival and improves the predictive ability
of the R-IPI score in diffuse large B-cell lymphoma patients. Br J Cancer. 2014;111(1):55-60.
14.Yao Z, Deng L, Xumonette ZY, Manyam GC, Jain P, Tzankov A, et al. Concordant bone
marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical
and biological entity in the era of immunotherapy. Leukemia. 2017;32(2):353-363.
15.Warwick R, Mediratta N, Shackcloth M, Shaw M, Mcshane J, Poullis M. Preoperative red
cell distribution width in patients undergoing pulmonary resections for non-small-cell
lung cancer. Eur J Cardiothorac Surg. 2014;45(1):108-113.
16.Albayrak S, Zengin K, Tanik S, Bakirtas H, Imamoglu A, Gurdal M. Red cell distribution
width as a predictor of prostate cancer progression. Asian Pac J Cancer Prev. 2014;15(18):7781-7784.
17.Monika P, Dorota H, Agnieszka S, Arkadiusz M, Sylwia C, Marek H, et al. Assessment
of red blood cell distribution width as a prognostic marker in chronic lymphocytic
leukemia. Oncotarget. 2016;7(22): 32846-32853.
18.Li Z, Hong N, Robertson M, Wang C, Jiang G. Preoperative red cell distribution width
and neutrophil-to-lymphocyte ratio predict survival in patients with epithelial ovarian
cancer. Sci Rep. 2017;7:43001.
19.Li B, You Z, Xiong XZ, Zhou Y, Wu SJ, Zhou RX, et al. Elevated red blood cell distribution
width predicts poor prognosis in hilar cholangiocarcinoma. Oncotarget. 2017;8(65):109468-109477.
20.Wan GX, Chen P, Cai XJ, Li LJ, Yu XJ, Pan DF, et al. Elevated red cell distribution
width contributes to a poor prognosis in patients with esophageal carcinoma. Clin Chim Acta. 2016;452:199-203.
21.Koma Y, Onishi A, Matsuoka H, Oda N, Yokota N, Matsumoto Y, et al. Increased red blood
cell distribution width associates with cancer stage and prognosis in patients with
lung cancer. Plos One. 2013;8(11):e80240.
22.Seretis C, Seretis F, Lagoudianakis E, Gemenetzis G, Salemis NS. Is red cell distribution
width a novel biomarker of breast cancer activity? Data from a pilot study. J Clin Med Res. 2013 ;5(2):121-126.
23.Miyamoto K, Inai K, Takeuchi D, Shinohara T, Nakanishi T. Relationships among red
cell distribution width, anemia, and interleukin-6 in adult congenital heart disease.
Circ J. 2015;79(5): 1100-1106.
24.G L, G T, M M, GL S, G Z, GC G. Relation between red blood cell distribution width
and inflammatory biomarkers in a large cohort of unselected outpatients. Arch Pathol Lab Med. 2009; 133(4):628-632
25.Vayá A, Sarnago A, Fuster O, Alis R, Romagnoli M. Influence of inflammatory and lipidic
parameters on red blood cell distribution width in a healthy population. Clin Hemorheol Microcirc. 2015;59(4):379-385.
26.Rhodes CJ, Howard LS, Busbridge M, Ashby D, Kondili E, Gibbs JS, et al. Iron Deficiency
and Raised Hepcidin in Idiopathic Pulmonary Arterial Hypertension : Clinical Prevalence,
Outcomes, and Mechanistic Insights.J Am Coll Cardiol. 2011;58(3):300-309.
27.Periša V, Zibar L, Sinčićpetričević J, Knezović A, Periša I, Barbić J. Red blood cell
distribution width as a simple negative prognostic factor in patients with diffuse
large B-cell lymphoma: a retrospective study. Croat Med J. 2015;56(4):334-343.
28.Goyal H, Gupta S, Singla U. Level of red cell distribution width is affected by various
factors. Clin Chem Lab Med. 2016;54(12):e387.
29.Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
30.Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454(7203): 436-444.
31.Tete S, Nicoletti M, Saggini A, Maccauro G, Rosati M, Conti F, et al. Nutrition and
cancer prevention.Int J Immunopathol Pharmacol. 2012;25(3):573-581.
32.Liebman H. Other immune thrombocytopenias. Semin Hematol. 2007;44(4 Suppl 5):S24-34.
33.Bloomfield CD, Mckenna RW, Brunning RD. Significance of Haematological Parameters
in the Non-Hodgkin's Malignant Lymphomas. Br J Haematol. 1976;32(1):41-46.
34.Conlan MG, Armitage JO, Bast M, Weisenburger DD. Clinical significance of hematologic
parameters in non-Hodgkin's lymphoma at diagnosis. Cancer. 1991;67(5):1389-1395.
35.Groden C. Tumor-platelet interaction in solid tumors. Int J Cancer. 2012;130(12):2747–2760.
36.Jain N, Roberts KG, Jabbour E, Patel K, Eterovic AK, Chen K, et al. Ph-like acute
lymphoblastic leukemia: a high-risk subtype in adults. Blood. 2017;129(5):572-581.
37.Fei L, Yang Y, Jin F, Dehoedt C, Jia R, Zhou Y, et al. Clinical characteristics and
prognostic factors of adult hemophagocytic syndrome patients: a retrospective study
of increasing awareness of a disease from a single-center in China. Orphanet J Rare Dis. 2015;10(1):1-9.
38.Jurczyszyn A, Radocha J, Davila J, Fiala MA, Gozzetti A, Grząśko N, et al. Prognostic
indicators in primary plasma cell leukaemia: a multicentre retrospective study of
117 patients. Br J Haematol. 2018;180(6):831-839.
39.Chen LP, Lin SJ, Yu MS. Prognostic value of platelet count in diffuse large B-cell
lymphoma. Clin Lymphoma Myeloma Leuk. 2012;12(1):32-37.
40.Ochi Y, Kazuma Y, Hiramoto N, Ono Y, Yoshioka S, Yonetani N, et al. Utility of a simple
prognostic stratification based on platelet counts and serum albumin levels in elderly
patients with diffuse large B cell lymphoma. Ann Hematol. 2017;96(1):1-8.
41.Kamran N,Li Y,Sierra M,et al. Melanoma induced immunosuppression is mediated by hematopoietic
dysregulation. OncoImmunology, 2017:e1408750.
42.Zhou S, Fang F, Chen H, Zhang W, Chen Y, Shi Y, et al. Prognostic significance
of the red blood cell distribution width in diffuse large B-cell lymphoma patients.
Oncotarget. 2017;8(25):40724-40731.
43.Kang L, Chen W, Petrick NA, Gallas BD. Comparing two correlated C indices with
right‐censored survival outcome: a one‐shot nonparametric approach. Stat Med.2015;34(4):685-703.